Product Name | Nifedipine |
Description |
L-type Ca channel blocker |
Purity | >98% |
CAS No. | 21829-25-4 |
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.34 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble to 100 mM in DMSO |
Source | Synthetic |
Appearance | Yellow solid |
SMILES | CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC |
InChI | InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 |
InChIKey | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
Safety Phrases |
Classification: Toxic. May be harmful or fatal if inhaled, swallowed or absorbed through skin. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Risk Phrases: R20/21/22- Harmful by inhalation, in contact with skin and if swallowed R60 - May impair fertility R61 - May cause harm to the unborn child Hazard Phrases: H302 |
Cite This Product | Nifedipine (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-309) |
Alternative Names | Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate |
Research Areas | Calcium Channels, Ion Channels, Neuroscience, Voltage-Gated Calcium Channels |
PubChem ID | 4485 |
Scientific Background | Nifedipine is a dihydropyridine calcium channel blocker primarily used to treat hypertension and angina. In neuroscience, it has been employed to investigate the role of L-type calcium channels in neuronal function and neurovascular regulation. Nifedipine’s ability to modulate calcium influx has implications for neuroprotection, particularly in ischemic injury and neurodegenerative conditions where calcium overload contributes to cell death. Its use in experimental models helps elucidate calcium-dependent signaling pathways in neurons and glial cells. |
References |
1. Dalal J.J., Griffiths B.E. and Henderson A.H. (1981) Br Heart J. 46(2): 230-231. 2. Thompson A.E., Pope J.E. (2005) Rheumatology. 44(2): 145-150. |
Reviews
There are no reviews yet.